EP3347012A4 - Muskarinische kombinationen und deren verwendung zur bekämpfung hypocholinergischer störungen des zentralen nervensystems - Google Patents

Muskarinische kombinationen und deren verwendung zur bekämpfung hypocholinergischer störungen des zentralen nervensystems Download PDF

Info

Publication number
EP3347012A4
EP3347012A4 EP16845102.9A EP16845102A EP3347012A4 EP 3347012 A4 EP3347012 A4 EP 3347012A4 EP 16845102 A EP16845102 A EP 16845102A EP 3347012 A4 EP3347012 A4 EP 3347012A4
Authority
EP
European Patent Office
Prior art keywords
muscarinic
combating
combinations
nervous system
central nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16845102.9A
Other languages
English (en)
French (fr)
Other versions
EP3347012A1 (de
Inventor
Thomas N. Chase
Kathleen E. Clarence-Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chase Pharmaceuticals Corp
Original Assignee
Chase Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chase Pharmaceuticals Corp filed Critical Chase Pharmaceuticals Corp
Publication of EP3347012A1 publication Critical patent/EP3347012A1/de
Publication of EP3347012A4 publication Critical patent/EP3347012A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP16845102.9A 2015-09-11 2016-09-09 Muskarinische kombinationen und deren verwendung zur bekämpfung hypocholinergischer störungen des zentralen nervensystems Withdrawn EP3347012A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562217081P 2015-09-11 2015-09-11
US201662351382P 2016-06-17 2016-06-17
PCT/US2016/050907 WO2017044714A1 (en) 2015-09-11 2016-09-09 Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system

Publications (2)

Publication Number Publication Date
EP3347012A1 EP3347012A1 (de) 2018-07-18
EP3347012A4 true EP3347012A4 (de) 2019-04-17

Family

ID=58240063

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16845102.9A Withdrawn EP3347012A4 (de) 2015-09-11 2016-09-09 Muskarinische kombinationen und deren verwendung zur bekämpfung hypocholinergischer störungen des zentralen nervensystems

Country Status (3)

Country Link
EP (1) EP3347012A4 (de)
CA (1) CA2996719A1 (de)
WO (1) WO2017044714A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2804215C (en) 2009-07-22 2019-10-01 Eric Elenko Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
AU2019346626B2 (en) 2018-09-28 2022-06-02 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarinic receptor activation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016144749A1 (en) * 2015-03-06 2016-09-15 Chase Thomas N Oxybutynin-xanomeline transdermal therapeutic system combinations
WO2016144719A1 (en) * 2015-03-06 2016-09-15 Chase Thomas N Oxybutynin transdermal therapeutic system muscarinic agonist combination
WO2017015349A1 (en) * 2015-07-20 2017-01-26 Chase Pharmaceuticals Corporation Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders
WO2017044693A1 (en) * 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
WO2017147104A1 (en) * 2016-02-24 2017-08-31 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combinations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124176A1 (en) * 1999-12-16 2003-07-03 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US20130289019A1 (en) * 2012-04-26 2013-10-31 Amazing Grace, Inc. Methods of treating behaviorial and/or mental disorders
BR112015004902A2 (pt) * 2012-09-05 2017-07-04 Chase Pharmaceuticals Corp métodos e composição neutroprotetores anticolinérgicos

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016144749A1 (en) * 2015-03-06 2016-09-15 Chase Thomas N Oxybutynin-xanomeline transdermal therapeutic system combinations
WO2016144719A1 (en) * 2015-03-06 2016-09-15 Chase Thomas N Oxybutynin transdermal therapeutic system muscarinic agonist combination
WO2017015349A1 (en) * 2015-07-20 2017-01-26 Chase Pharmaceuticals Corporation Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders
WO2017044693A1 (en) * 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
WO2017147104A1 (en) * 2016-02-24 2017-08-31 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combinations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017044714A1 *

Also Published As

Publication number Publication date
EP3347012A1 (de) 2018-07-18
WO2017044714A1 (en) 2017-03-16
CA2996719A1 (en) 2017-03-16

Similar Documents

Publication Publication Date Title
EP3448389A4 (de) Chinazolin- und indolderivate zur behandlung von medizinischen störungen
EP3526319A4 (de) Verfahren und zusammensetzungen und zur behandlung von erkrankungen und störungen des zentralnervensystems
EP3481387A4 (de) Verfahren und zusammensetzungen zur behandlung von epileptischen erkrankungen
HRP20210518T1 (hr) Derivati 2,4-tiazolidindiona, namijenjeni liječenju poremećaja središnjeg živčanog sustava
EP3490603A4 (de) Zusammensetzungen und verfahren zur behandlung von masp-3 zur behandlung von verschiedenen erkrankungen und störungen
EP3183005A4 (de) Verfahren und zusammensetzungen zur behandlung von stoffwechselerkrankungen
EP3445352A4 (de) Zusammensetzungen zur behandlung von hyperkeratoseerkrankungen
EP3507371A4 (de) Verfahren und zusammensetzungen und zur behandlung von erkrankungen und störungen des nervensystems
HK1256721A1 (zh) 用於治療眼部病症的化合物和組合物
EP3474842A4 (de) Zusammensetzungen, vorrichtungen und verfahren zur behandlung von alkoholkonsumbedingter erkrankung
EP3347011A4 (de) Muscarinkombination und deren verwendung zur bekämpfung von hypocholinergen störungen des zentralen nervensystems
EP3506899A4 (de) Zusammensetzung und verfahren zur diagnose und behandlung von erkrankungen des lymphatischen systems
EP3374354A4 (de) Benzofuranderivate zur behandlung des zentralen nervensystems (zns) und anderen erkrankungen
EP3347012A4 (de) Muskarinische kombinationen und deren verwendung zur bekämpfung hypocholinergischer störungen des zentralen nervensystems
EP3206708A4 (de) Verfahren und zusammensetzungen zur behandlung von erkrankungen im zusammenhang mit strahlung
EP3265128A4 (de) Kombination aus transdermalem oxybutynintherapiesystem und muscarinrezeptoragonist
EP3131635A4 (de) Zusammensetzungen und verfahren zur behandlung oder prävention von neurodegenerativen erkrankungen
EP3110414A4 (de) Xanthonreiche pflanzenextrakte oder verbindungen davon zur modulierung von erkrankungen des zentralen nervensystems und von assoziierten erkrankungen
EP3468550A4 (de) Verwendung von lithiumbenzoat zur behandlung von störungen des zentralen nervensystems
EP3507277B8 (de) Hydroxynorketaminderivate zur behandlung von erkrankungen
ZA201806894B (en) (+)-azasetron for use in the treatment of ear disorders
ZA201700037B (en) Compounds for the treatment of seizures and other central nervous system disorders and conditions
PT3442537T (pt) (+)-azasetrom para utilização no tratamento de doenças do ouvido
AU2014900627A0 (en) Modulation of diseases of the central nervous system and related disorders
EP3247396A4 (de) Verfahren und zusammensetzungen zur behandlung von erkrankungen und -störungen

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180404

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031435000

Ipc: A61K0031216000

A4 Supplementary search report drawn up and despatched

Effective date: 20190318

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/454 20060101ALI20190312BHEP

Ipc: A61K 45/06 20060101ALI20190312BHEP

Ipc: A61K 31/216 20060101AFI20190312BHEP

Ipc: A61K 31/517 20060101ALI20190312BHEP

Ipc: A61K 31/4439 20060101ALI20190312BHEP

Ipc: A61K 31/4178 20060101ALI20190312BHEP

Ipc: A61K 9/70 20060101ALI20190312BHEP

Ipc: A61P 25/24 20060101ALI20190312BHEP

Ipc: A61K 31/166 20060101ALI20190312BHEP

Ipc: A61P 25/28 20060101ALI20190312BHEP

Ipc: A61P 25/18 20060101ALI20190312BHEP

Ipc: A61P 25/00 20060101ALI20190312BHEP

Ipc: A61P 25/14 20060101ALI20190312BHEP

Ipc: A61K 31/439 20060101ALI20190312BHEP

Ipc: A61P 43/00 20060101ALI20190312BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200623

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230331

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230310